Copied
 
 
2023, DKK
17.09.2024
Bruttoresultat

6.343'

Primær drift

-15.832'

Årets resultat

-12.679'

Aktiver

74.575'

Kortfristede aktiver

17.868'

Egenkapital

42.695'

Afkastningsgrad

-21 %

Soliditetsgrad

57 %

Likviditetsgrad

83 %

Resultat
17.09.2024
Årsrapport
2023
17.09.2024
2022
23.08.2023
2021
30.09.2022
2020
20.08.2021
2019
22.06.2020
2018
29.05.2019
Nettoomsætning
Bruttoresultat6.342.6383.583.313-1.889.181-1.316.333-1.076.593-425.906
Resultat af primær drift-15.832.327-10.359.954-4.338.992-3.586.654-1.695.687-470.380
Indtægter af kapitalandele (tilknyttede og associerede) 000000
Finansielle indtægter13.1716.81901.464013
Finansieringsomkostninger-904.540-1.192.429-696.369-529.013-218.277-649
Andre finansielle omkostninger-904.540-1.192.4290000
Resultat før skat-16.723.696-11.545.564-5.035.361-4.114.203-1.913.964-471.016
Resultat-12.678.902-6.483.189-4.090.429-3.677.944-1.728.628-368.700
Forslag til udbytte000000
Aktiver
17.09.2024
Årsrapport
2023
17.09.2024
2022
23.08.2023
2021
30.09.2022
2020
20.08.2021
2019
22.06.2020
2018
29.05.2019
Kortfristede varebeholdninger000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 9.603.0294.968.9085.285.7273.389.7801.339.547426.369
Likvider8.264.75626.584.5806.097.5918.804.8052.463.047721.740
Kortfristede aktiver17.867.78531.553.48811.383.31812.194.5853.802.5941.148.109
Immaterielle aktiver og goodwill56.386.10233.236.72521.271.46312.015.1716.062.2921.414.237
Finansielle anlægsaktiver192.73173100138.000153.600
Materielle aktiver128.21459.017125.34360.20547.94619.340
Langfristede aktiver56.707.04733.296.47321.396.80612.075.3766.248.2381.587.177
Aktiver74.574.83264.849.96132.780.12424.269.96110.050.8322.735.286
Aktiver
17.09.2024
Passiver
17.09.2024
Årsrapport
2023
17.09.2024
2022
23.08.2023
2021
30.09.2022
2020
20.08.2021
2019
22.06.2020
2018
29.05.2019
Forslag til udbytte000000
Egenkapital42.695.41041.148.1196.228.6386.504.0673.630.4732.359.100
Hensatte forpligtelser1.975.763482.7152.901.7321.867.388983.014161.149
Langfristet gæld til banker000000
Anden langfristet gæld00316.5632.058.142215.1850
Leverandører af varer og tjenesteydelser3.241.1891.392.713369.783702.624561.975103.371
Kortfristede forpligtelser21.504.53314.665.05610.609.0406.731.5072.019.212215.037
Gældsforpligtelser29.903.65923.219.12723.649.75415.898.5065.437.345215.037
Forpligtelser29.903.65923.219.12723.649.75415.898.5065.437.345215.037
Passiver74.574.83264.849.96132.780.12424.269.96110.050.8322.735.286
Passiver
17.09.2024
Nøgletal
17.09.2024
Årsrapport
2023
17.09.2024
2022
23.08.2023
2021
30.09.2022
2020
20.08.2021
2019
22.06.2020
2018
29.05.2019
Afkastningsgrad -21,2 %-16,0 %-13,2 %-14,8 %-16,9 %-17,2 %
Dækningsgrad Na.Na.Na.Na.Na.Na.
Resultatgrad Na.Na.Na.Na.Na.Na.
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning -29,7 %-15,8 %-65,7 %-56,5 %-47,6 %-15,6 %
Payout-ratio Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal -1.750,3 %-868,8 %-623,1 %-678,0 %-776,9 %-72.477,7 %
Soliditestgrad 57,3 %63,5 %19,0 %26,8 %36,1 %86,2 %
Likviditetsgrad 83,1 %215,2 %107,3 %181,2 %188,3 %533,9 %
Resultat
17.09.2024
Gæld
17.09.2024
Årsrapport
17.09.2024
Nyeste:01.04.2023- 31.03.2024(offentliggjort: 17.09.2024)
Information om virksomhedens regnskabsklasse:The annual report has been prepared in accordance with Danish financial statement legislation as well as generally accepted accounting principles. The annual report has been prepared in accordance with the provisions of the Danish Financial Statements Act governing Reporting class B. Some provisions from reporting class C has been adopted. The accounting policies have been changed from last year.
Beretning
17.09.2024
Dato for ledelsens godkendelse af årsrapporten:2024-05-30
Beskrivelse af usikkerhed ved indregning eller måling:Research and development costs and collaboration with the healthcare sector are uncertain and difficult to predict when we develop deep tech medical devices. The cost and raising of capital for the continued journey depends on the investment climate, which is relatively risk averse, and therefore realistic. We have so far been and will also going forward stay cost-conscious and conservative.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Board of Directors and The Executive Board have today considered and adopted the annual report for 1 April 2023 - 31 March 2024 for Cerebriu A/S.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Cerebriu A/S's primary activities is to operate in the research and development, service, and sale of technology-based products in the healthcare sector, including activities related to enhancing radiological productivity, efficiency, workflow and quality through integration and automated brain imaging.